Last reviewed · How we verify
Ovcon® 35 Fe
At a glance
| Generic name | Ovcon® 35 Fe |
|---|---|
| Also known as | Femcon® Fe, Norethindrone/Ethinyl Estradiol (generic name) |
| Sponsor | Teva Pharmaceuticals USA |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation (NA)
- Oral Contraceptive (OC) Progestin Dose and Breast Proliferation (NA)
- Study Of Lybrel In Relation To Venous Thromboembolism
- Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions (PHASE1)
- Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ovcon® 35 Fe CI brief — competitive landscape report
- Ovcon® 35 Fe updates RSS · CI watch RSS
- Teva Pharmaceuticals USA portfolio CI